Who owns Hemab Therapeutics?
1 of the world’s richest people holds Hemab Therapeutics in our tracked profiles.
About
Hemab Therapeutics is a clinical-stage biotech company developing treatments for bleeding and blood-clotting disorders. Its lead candidate, sutacimig, is in trials for Glanzmann thrombasthenia and Factor VII deficiency.
Source: Hemab Therapeutics Holdings, Inc. IPO prospectus (424B4) (filed 2026-05-01) ↗. Summary in our own words.
Billionaire holders
- Len BlavatnikMediaStakeHemab Therapeutics Holdings - 13D via AI DEN-MAB LLC after IPO: 4,876,344 shares · 10.4% · as of May 2026source ↗
Each row is a sourced entry from that person’s profile. Stakes are as of the date shown, not today.
Recent SEC filings
No Form 4 insider trades in Hemab Therapeutics from the holders above in the last 90 days.
Form 4 insider trades post within 2 business days. New to filings? Read Filings 101.
Recent moves
No digest stories about Hemab Therapeutics yet. The archive grows every morning.
Related
Other companies held by the same people.